Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand.

Medicines (Basel, Switzerland) Pub Date : 2023-03-08 DOI:10.3390/medicines10030023

Olivier Bruyère, Johann Detilleux, Jean-Yves Reginster

{"title":"Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand.","authors":"Olivier Bruyère, Johann Detilleux, Jean-Yves Reginster","doi":"10.3390/medicines10030023","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo.Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered.Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time.Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not.","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059797/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicines (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medicines10030023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: The aim of this study was to evaluate the cost-effectiveness of different glucosamine formulations and preparations used for the management of osteoarthritis in Thailand compared with placebo.

Methods: We used a validated model to simulate the individual patient Utility score from aggregated data available from 10 different clinical trials. We then used the Utility score to calculate the quality-adjusted life year (QALY) over 3 and 6 months treatment period. We used the public costs of glucosamine products available in Thailand in 2019 to calculate the incremental cost-effectiveness ratio. We separated the analyses for prescription-grade crystalline glucosamine sulfate (pCGS) and other formulations of glucosamine. A cost-effectiveness cut-off of 3.260 USD/QALY was considered.

Results: Irrespective of the glucosamine preparation (tablet or powder/capsule), the data show that pCGS is cost-effective compared with placebo over a 3 and 6 months. However, the other glucosamine formulations (e.g., glucosamine hydrochloride) never reached the breakeven point at any time.

Conclusions: Our data show that pCGS is cost-effective for the management of osteoarthritis in the Thai context while other glucosamine formulations are not.

查看原文本刊更多论文

目前在泰国销售的不同氨基葡萄糖制剂的卫生技术评价。

目的:本研究的目的是评估不同的氨基葡萄糖制剂和制剂用于治疗骨关节炎在泰国与安慰剂比较的成本效益。方法:我们使用一个经过验证的模型来模拟来自10个不同临床试验的汇总数据的个体患者效用评分。然后，我们使用效用评分来计算3个月和6个月治疗期间的质量调整生命年(QALY)。我们使用泰国2019年可用的氨基葡萄糖产品的公共成本来计算增量成本效益比。我们将处方级结晶硫酸氨基葡萄糖(pCGS)和其他配方的氨基葡萄糖分离分析。考虑了3.260美元/QALY的成本效益截止值。结果:无论何种葡萄糖胺制剂(片剂或粉剂/胶囊)，数据显示，与安慰剂相比，pCGS在3个月和6个月内具有成本效益。然而，其他氨基葡萄糖制剂(如盐酸氨基葡萄糖)在任何时候都没有达到盈亏平衡点。结论:我们的数据显示，pCGS在泰国治疗骨关节炎方面具有成本效益，而其他氨基葡萄糖制剂则不然。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicines (Basel, Switzerland)

自引率

0.00%

发文量

审稿时长

6 weeks